SCHEMBL28680437

SCHEMBL28680437

N#Cc1c(F)cc(Br)cc1NC1CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.35
PIM1 P11309 2/20 0.34
PIM2 Q9P1W9 2/20 0.34
ROCK2 O75116 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
GRM2 Q14416 1/20 0.31
PDE4B Q07343 2/20 0.31
IRAK4 Q9NWZ3 1/20 0.30
CTSV O60911 1/20 0.30
PLAT P00750 1/20 0.30
CTSL P07711 1/20 0.30
CTSB P07858 1/20 0.30
CTSH P09668 1/20 0.30
CTSS P25774 1/20 0.30
CASP14 P31944 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14029994 0.94 KMT2A (0.40) TRPV4MEN1KMT2AL3MBTL1CTSV
SCHEMBL3624322 0.93 PIM1 (0.43) PIM1PIM2ROCK2TDP1
SCHEMBL3624321 0.93 PIM1 (0.43) PIM1PIM2ROCK2TDP1
SCHEMBL29427903 0.90 MAPK1 (0.36) TRPV4PIM1PIM2MEN1KMT2A
SCHEMBL3631931 0.90 MAPK1 (0.36) TRPV4PIM1PIM2MEN1KMT2A
SCHEMBL12820367 0.87 SCN5A (0.35) PIM1PIM2MEN1KMT2AL3MBTL1
SCHEMBL3630162 0.84 BCL6 (0.36) GRM2IRAK4CTSK
SCHEMBL3630158 0.84 BCL6 (0.36) GRM2IRAK4CTSK
SCHEMBL5005581 0.79 PTGS1 (0.36) PIM1PDE4BIRAK4
SCHEMBL5005536 0.79 PTGS1 (0.34) PIM1MEN1KMT2ANPC1IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113767106-B Oxazaquinazolin-7 (8H) -ones, preparation method and medical application thereof 劲方医药科技(上海)有限公司 2024-02-20 CN disclosed
US-20220251109-A1 OXAAZAQUINAZOLINE-7(8H)-KETONE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2022-08-11 US disclosed
EP-3964516-A1 OXAAZAQUINAZOLINE-7(8H)-KETONE COMPOUND, PREPARATION METHOD THERFOR AND PHARMACEUTICAL APPLICATION THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2022-03-09 EP disclosed
CN-113767106-A Oxaazaquinazolin-7 (8H) -ones, their preparation and pharmaceutical use 劲方医药科技(上海)有限公司 2021-12-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220251109-A1 OXAAZAQUINAZOLINE-7(8H)-KETONE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF KRAS, NRAS, WEE1 TRPV4 4382/4885PIM1 1277/4885PIM2 1757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.